Pedicloryl (Chloral Hydrate) in Pediatric Patients
Pedicloryl (chloral hydrate) is indicated for children 6 to under 12 years at 2 mL every 6 hours (not exceeding 4 doses in 24 hours), but its use requires careful patient selection and continuous cardiopulmonary monitoring given the risk of respiratory depression, particularly in children under 2 years who face a black box warning for fatal respiratory complications. 1, 2
Indications and Appropriate Use
Chloral hydrate is primarily used for:
- Procedural sedation for diagnostic imaging (MRI, CT) in children
- Dental procedures requiring moderate sedation
- Nocturnal sedation in pediatric patients
The drug is most effective in younger children (under 2 years) and lighter weight patients 3. Success rates for sedation reach 95-100% when proper dosing and patient selection criteria are followed 4, 5.
Dosing Guidelines
Standard Dosing
- Initial dose: 40-60 mg/kg orally (standard dose range)
- Reduced dose: <40 mg/kg (does not affect effectiveness but may increase failure rates) 4
- High dose: >60 mg/kg (may be needed in specific populations)
- Additional dose: 10-20 mg/kg can be given 15 minutes after initial dose if needed 4
FDA-Approved Dosing (Pedicloryl)
For children 6 to under 12 years: 2 mL every 6 hours, maximum 4 doses in 24 hours 1. For children under 6 years, physician consultation is required 1.
Route-Specific Considerations
Rectal administration achieves comparable success rates (84%) to oral administration (91%) but with significantly shorter onset time (6.36 minutes faster) and zero vomiting rate versus 20% with oral route 6, 7. The rectal route provides a viable alternative when oral administration is problematic.
Patient Selection Criteria
Appropriate Candidates
- ASA Class I and II patients are ideal candidates 2
- Outpatients, patients undergoing hearing screening, and those with sleep deprivation have higher success rates 3
- Younger children (<2 years) and lighter weight patients respond more predictably 8, 3
High-Risk Patients Requiring Additional Consideration
Children with the following characteristics have 2.2 times higher likelihood of requiring additional doses:
- Age >2 years 4
- Heavier weight 3
- History of previous sedation or sedation failure 3
- Undergoing MRI or multiple procedures simultaneously 3
ASA Class III-IV patients, children with anatomic airway abnormalities, or moderate-to-severe tonsillar hypertrophy require individual assessment and may not be appropriate candidates 2.
Critical Contraindications and Warnings
Black Box Warning
Promethazine (often combined with chloral hydrate) carries a black box warning for fatal respiratory depression in children under 2 years 2. This combination should be avoided in this age group.
Absolute Contraindications (per FDA label)
Do not use if the child has:
Relative Contraindications
- Concurrent use of sedatives or tranquilizers (increases drowsiness effect) 1
- Compromised or ill preterm infants (risk of trichloroacetic acid and trichloroethanol accumulation) 9
Safety Precautions and Monitoring Requirements
Mandatory Monitoring Standards
Continuous monitoring by personnel trained in pediatric advanced life support is required from drug administration until discharge criteria are met 2, 5. This includes:
- Continuous pulse oximetry (SpO2)
- Vital signs monitoring
- Respiratory rate and pattern assessment
- Level of consciousness
Emergency Preparedness
An emergency cart with age-appropriate equipment must be immediately accessible, including:
- Oral and nasal airways
- Bag-valve-mask device
- Laryngoscope blades and tracheal tubes
- Supraglottic devices (LMAs)
- Intravenous catheters
- Blood pressure cuffs 2
For non-hospital facilities, a protocol for immediate EMS activation must be established 2.
Adverse Events and Management
Common Adverse Events
- Hypoxia (mild: SpO2 90-95%): Occurs in 5-9% of cases, usually resolves spontaneously 5
- Prolonged sedation: Most common postoperative event 10
- Vomiting: 20% with oral route, 0% with rectal route 6
- Paradoxical excitability: Especially in children 1
Serious Adverse Events
Severe respiratory complications (SpO2 <85%) occur in <1% of cases but can be life-threatening 5. Deaths have been reported, primarily due to:
- Dosing errors
- Use of multiple sedatives
- Inadequate patient selection (underestimated severity of underlying disease) 10, 5
Critical Pitfall
Re-sedation after discharge can occur due to prolonged drug effects, particularly dangerous in infants transported in car safety seats where airway obstruction may develop 2. Two adults should accompany children in car seats during transport.
Special Populations
Neonates and Infants
Use with extreme caution in preterm infants due to:
- Accumulation of trichloroacetic acid and trichloroethanol in compromised infants
- Competition for hepatic glucuronidation with bilirubin
- Frequent serum bilirubin monitoring is mandatory with multiple dosing 9
Combination Therapy
Low-dose chloral hydrate (10-25 mg/kg) combined with other sedating medications is commonly used in pediatric dental practice 2, but this increases risk and requires heightened vigilance for respiratory depression.
Discharge Criteria
Two adults must accompany children still in car safety seats 2. Patients must meet standard recovery criteria before discharge, but extended observation is necessary given chloral hydrate's prolonged duration of action compared to shorter-acting agents.
Key Clinical Pearls
- Titrate to effect: Wait for full effect of previous dose (peak EEG effect at ~4.8 minutes for midazolam comparison) before additional dosing 2
- Sleep deprivation improves success rates 3
- Reduced doses (<50 mg/kg) do not increase failure rates but standard dosing (40-60 mg/kg) remains preferred 4
- Rectal route eliminates vomiting risk and provides faster onset 6, 7
- Success rate drops significantly for MRI procedures and multiple simultaneous procedures - consider alternative agents 3